Glaxosmithkline LLC

Glaxosmithkline Intellectual Property (No.2) Limited

Novartis Ag

Xinrong Tian

William Henry Miller

Neil W Johnson

Steven David Knight

Kenneth Allen Newlander

Stuart Paul Romeril

Sharad Kumar Verma

Meagan B Rouse

Joelle Lorraine Burgess

Louis Lafrance

Jiri Kasparec

Dominic Suarez

Louis Vincent Lafrance, Iii

Juan I Luengo

Mark James Schulz

Seth Wilson Grant

Dai-Shi Su

James Brackley, Iii

Charles William Blackledge, Jr

Louis V LaFrance, Iii

Celine Duquenne

Jerry Leroy Adams

Alex Gregory Waterson

Vipulkumar Kantibhai Patel

Scott Howard Dickerson

Jeffrey Michael Axten

Christopher Roland Wellaway

George Adjabeng

John Stellwagen

David Edward Uehling

Tara Renae Rheault

Francis Louis Atkinson

Kevin Kuntz

Michael Lee Moore

Keith Hornberger

Brian Wilson

Kimberly Petrov

Jeffrey M Ralph

Maria Cichy-Knight

Allison K Dunn

Mark Schulz

Shared Kumar Verma

Gregory Schaaf

Iii James A Brackley

Iii Alan Peterson Graves

Kenneth C Mcnulty

Iii Louis Vincent Lafrance

Jr Charles William Blackledge

Louis V Lafrance Iii

Louis Vincent Iii Lafrance

Vipulkumar Kantibhai Patei

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. 

Enhancer of zeste homolog 2 inhibitors

This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them. 

Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.

Indoles

This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.

Cyclopropylamines as LSD1 inhibitors

Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.

Azaindazoles

Herein are disclosed indazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.

Indazoles

Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful in treating cancer. 

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

Benzene sulfonamide thiazole and oxazole compounds

The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R, R, and Rare defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Chemical compounds

Growing community of inventors

Collegeville, PA, United States of America

Xinrong Tian